Literature DB >> 23481023

The PEA-15/PED protein regulates cellular survival and invasiveness in colorectal carcinomas.

Verena Funke1, Judith Lehmann-Koch, Michèle Bickeböller, Axel Benner, Katrin E Tagscherer, Kerstin Grund, Marco Pfeifer, Esther Herpel, Peter Schirmacher, Jenny Chang-Claude, Hermann Brenner, Michael Hoffmeister, Wilfried Roth.   

Abstract

The PEA-15/PED (phosphoprotein enriched in astrocytes 15kD/phosphoprotein enriched in diabetes) protein is a multifunctional phosphoprotein involved in various signaling pathways which determine survival, proliferation, and migration of cancer cells. Here, we investigated the expression and cellular functions of PEA-15 in colorectal carcinoma (CRC). PEA-15 is expressed in the majority of human CRC, predominantly in well differentiated tumor areas. A tissue microarray analysis of 1262 human CRC specimens from the DACHS study showed that PEA-15 expression is significantly associated with a low pT stadium as defined by limited invasion into the bowel wall. Moreover, patients with PEA-15-positive CRC exhibited a significantly longer tumor-specific survival time. To investigate the functional relevance of PEA-15 expression on a cellular level, we over-expressed PEA-15 in several CRC cell lines. Increased expression of PEA-15 resulted in a strong inhibition of clonogenicity, proliferation, and invasiveness of CRC cells. These effects were associated with a PEA-15-dependent down-regulation of integrin αvβ5 as well as with elevated levels of the phosphorylated MAP kinase ERK1/2. Moreover, expression of PEA-15 resulted in significant protection from cell death induced by cytotoxic drugs (5-FU, cisplatin), by the death ligand TRAIL, or by serum withdrawal. In conclusion, the PEA-15 protein regulates invasiveness, proliferation, and apoptosis resistance in CRC cells. PEA-15 might play an important role in chemoresistance, progression and metastasis in CRC.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23481023     DOI: 10.1016/j.canlet.2013.02.053

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Authors:  G Renner; H Janouskova; F Noulet; V Koenig; E Guerin; S Bär; J Nuesch; F Rechenmacher; S Neubauer; H Kessler; A-F Blandin; L Choulier; N Etienne-Selloum; M Lehmann; I Lelong-Rebel; S Martin; M Dontenwill
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

2.  Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells.

Authors:  Cristina Quintavalle; Stefania Di Costanzo; Ciro Zanca; Immaculada Tasset; Alessandro Fraldi; Mariarosaria Incoronato; Peppino Mirabelli; Maria Monti; Andrea Ballabio; Piero Pucci; Ana Maria Cuervo; Gerolama Condorelli
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

3.  Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.

Authors:  Xinhua Xie; Hailin Tang; Yanan Kong; Minqing Wu; Xiangsheng Xiao; Lu Yang; Jie Gao; Weidong Wei; Jangsoon Lee; Chandra Bartholomeusz; Naoto T Ueno; Xiaoming Xie
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

Review 4.  Thioredoxin promotes survival signaling events under nitrosative/oxidative stress associated with cancer development.

Authors:  Hugo P Monteiro; Fernando T Ogata; Arnold Stern
Journal:  Biomed J       Date:  2017-07-29       Impact factor: 4.910

5.  Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin.

Authors:  Shahana Dilruba; Alessia Grondana; Anke C Schiedel; Naoto T Ueno; Chandra Bartholomeusz; Jindrich Cinatl; Katie-May McLaughlin; Mark N Wass; Martin Michaelis; Ganna V Kalayda
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

Review 6.  On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities.

Authors:  Yufeng Wei
Journal:  Pharmaceuticals (Basel)       Date:  2015-07-31

Review 7.  Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.

Authors:  Fiona H Greig; Graeme F Nixon
Journal:  Pharmacol Ther       Date:  2014-03-20       Impact factor: 12.310

8.  Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.

Authors:  Cristina Quintavalle; Sravanth Kumar Hindupur; Luca Quagliata; Pierlorenzo Pallante; Cecilia Nigro; Gerolama Condorelli; Jesper Bøje Andersen; Katrin Elisabeth Tagscherer; Wilfried Roth; Francesco Beguinot; Markus Hermann Heim; Charlotte Kiu Yan Ng; Salvatore Piscuoglio; Matthias Sebastian Matter
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

9.  PEA-15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective Mediator in the Vasculature and Is Regulated During Neointimal Hyperplasia.

Authors:  Fiona H Greig; Simon Kennedy; George Gibson; Joe W Ramos; Graeme F Nixon
Journal:  J Am Heart Assoc       Date:  2017-09-11       Impact factor: 5.501

10.  ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15.

Authors:  Shuang Wang; Caixia Wang; Yuexin Hu; Xiao Li; Shan Jin; Ouxuan Liu; Rui Gou; Yuan Zhuang; Qian Guo; Xin Nie; Liancheng Zhu; Juanjuan Liu; Bei Lin
Journal:  J Exp Clin Cancer Res       Date:  2020-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.